Abstract
Major epidemics of Chikungunya have re-emerged with millions of cases worldwide. What was once largely a tropical disease in poorer countries is now recognized as a major global health issue. The disease is perpetuated by the alphavirus Chikungunya, and is transmitted by Aedes mosquitoes. The infection is highly symptomatic, with fever, skin rash and incapacitating arthralgia, which can evolve to chronic arthritis and rheumatism in elderly patients. Mother-to-child transmission, encephalitis, Guillain-Barré syndrome and deaths have been noted. In this article, we will highlight the epidemiological, clinical, virological and immunological aspects of the disease and mention the therapies that have been used during recent epidemics. Novel prevention measures to control the mosquito and a new vaccine are highly warranted.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Aedes / drug effects
-
Aedes / virology
-
Alphavirus Infections* / diagnosis
-
Alphavirus Infections* / epidemiology
-
Alphavirus Infections* / prevention & control
-
Animals
-
Chikungunya virus*
-
Communicable Diseases, Emerging* / diagnosis
-
Communicable Diseases, Emerging* / epidemiology
-
Communicable Diseases, Emerging* / prevention & control
-
Encephalitis / pathology
-
Female
-
Global Health
-
Humans
-
Insect Repellents / administration & dosage
-
Insect Vectors / drug effects
-
Insect Vectors / virology
-
Male
-
Pregnancy
-
Pregnancy Complications, Infectious / diagnosis
-
Pregnancy Complications, Infectious / epidemiology
-
Pregnancy Complications, Infectious / prevention & control
-
Vaccination
-
Viral Vaccines / administration & dosage
Substances
-
Insect Repellents
-
Viral Vaccines